We chose Erbb2 and Wnt1 as the initiating oncogenes, because their gene products activate two distinct pathways that are frequently altered in human breast cancer (Klaus and Birchmeier, 2008; Baselga and Swain, 2009). This evidence concerns the gene ERBB2 and breast carcinoma.